Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA
Main Authors: Kazi, Dhruv S., Penko, Joanne, Coxson, Pamela G., Moran, Andrew E., Ollendorf, Daniel A., Tice, Jeffrey A., Bibbins-Domingo, Kirsten
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2017
Assuntos:
Research Letter
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817484/
https://ncbi.nlm.nih.gov/pubmed/28829863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.9924
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares